Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | YAP1 | P46937 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612929 | 0.84 | SMN1; SMN2 (0.53) | LNPEPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL31466671 | 0.81 | TMEM97 (0.53) | MEN1KMT2ANPSR1 | |
| SCHEMBL21612907 | 0.80 | USP30 (0.50) | LNPEPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL23348710 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL30012105 | 0.79 | GPR119 (0.53) | LNPEPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL30011475 | 0.78 | GPR119 (0.52) | LNPEPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL3580284 | 0.78 | GPR119 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL13198829 | 0.78 | SMN1; SMN2 (0.50) | LNPEPSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL5273706 | 0.78 | GPR119 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2951356 | 0.78 | LNPEP (0.48) | LNPEPSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | LNPEP 2574/4885SMN1; SMN2 3443/4885NPC1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.